By Abraham Ayuen, Senior Communications Specialist for SIAPS South Sudan. This post originally appeared on MSH’s website. Six-year-old Yohana Peter clutched a bottle of mango juice as he waited for his medication outside a pharmacy at Al Sabah Children’s Hospital in Juba, South Sudan. Seated next to his mother on a metal bench, Yohana looked anxious. […]
Archive | Essential MedicinesRSS feed for this section
By Tsion Issayas, Communications Manager for SIAPS Ethiopia. This post originally appeared on MSH’s website. Aster Amanuel Desalegn lives in Debre Markos, 190 miles from the Ethiopian capital of Addis Ababa. She is a 70-year-old mother of four and grandmother of two. Her granddaughters, Emuye, 6, and Blen, 8, live with her. On a trip back […]
By Jane Briggs, Principal Technical Advisor More than 900,000 children die of pneumonia each year (more than malaria, measles, and HIV/AIDS combined), according to the World Health Organization. Many of these cases go undiagnosed and untreated. How can this be when we know what works? A five-day, twice-daily amoxicillin regimen—in either dispersible tablet (DT) or oral […]
Good Practices for the Dispensing of High-Cost Medicines in the Framework of an Integrated Supply System
Background Within the framework of health sector reform, the National Health Service (Servicio Nacional de Salud) of the Dominican Republic has been implementing the Integrated System for Medicine and Supply Management (Sistema Único de Gestión de Medicamentos e Insumos, or SUGEMI) in the public health services network. Its objective is to improve public access to […]
Promoting better use of medicines through the establishment of a National Essential Medicines Committee in Swaziland
The WHO estimates that more than 50% of all medicines are prescribed, dispensed or sold inappropriately, and that 50% of all patients fail to take them correctly. The overuse, underuse or misuse of medicines—also known as irrational use of medicines—results in wastage of scarce resources, increased risk of adverse drug reactions, and widespread health hazards, […]
Barillas E, Valdez C, Narvaez E, Vasquez G. Strategies Based on Evidence to Rationalize the High-Cost Medicines List in the Dominican Republic. Poster presented at the ISPOR 18th Annual European Congress in Milan, Italy, November 7-11, 2015.
Estrategias basadas en evidencia para la racionalización de la lista de medicamentos de alto costo en la Republica Dominicana
El Ministerio de Salud Pública (MSP) de República Dominicana organizó el Programa de Medicamentos de Alto Costo (PMAC) en 2008[i] con el propósito de facilitar atenciones clínicas a pacientes con patologías de muy baja prevalencia y alto costo de tratamiento, como cánceres refractarios a tratamientos convencionales, artritis reumatoide, hepatitis C y trasplante renal, entre otras. […]
Evidence-based strategies for the rationalization of the list of high-cost medicines in the Dominican Republic
The Ministry of Public Health (Ministerio de Salud Pública, or MSP) of the Dominican Republic organized the High-Cost Medicines Program (Programa de Medicamentos de Alto Costo, or PMAC) in 2008[i] to facilitate clinical care for patients with very rare diseases and high-cost treatment, such as cancers unresponsive to conventional treatments, rheumatoid arthritis, hepatitis C, and […]
Briggs J, Joshi MP, Yeager B, Diarra S. Ensuring access to and appropriate use of medicines for iCCM: It takes a system. Oral presentation at the 143rd American Public Health Association (APHA) Annual Meeting and Expo, Chicago, IL, USA. November 3, 2015.
How Public Funds Were Spent on Procurement of Medicines in Ukraine’s Hospitals: Interim Analysis for the Ministry of Health, Ukraine
Pharmaceuticals may constitute as much as 40% of the health care budget in low and middle-income countries, yet large portions of the population may lack access to even the most essential medicines. The limited public sector funds are frequently spent on ineffective or unnecessary medications. An analysis of past spending patterns on procurement of medicines will help the Ministry of Health policymakers and key government stakeholders in Ukraine for decisions on adopting the national Essential Medicines List (EML) in practice.
The purpose of this technical brief is twofold:
- To demonstrate the need to rationalize limited public funds for maximum health impact.
- To emphasize the need for proper selection of medicines based on WHO recommendations and the rationale for an EML as the sole basis for public sector procurement in Ukraine.
After summarizing high-level data analysis, this technical brief also takes a close look at insulins and analogues that account for the most expenditure.
This [report] is extremely useful. We need to use this information for the purpose of reforming the procurement system as well. The EML has become even more necessary now.”
– Dr. Ihor Perehinets, Deputy Minister of Health of Ukraine